▁of ▁ 3 0 , 0 0 0 ▁employees , ▁and ▁reported ▁US $ ▁ 9 ▁billion ▁in ▁combined ▁re venue . ▁On ▁November ▁ 9 , ▁ 2 0 0 6 , ▁the ▁companies ▁announced ▁that ▁the ▁mer ger ▁had ▁been ▁completed . ▁However , ▁the ▁Federal ▁Trade ▁Commission ▁ruled ▁that ▁this ▁ac quisition ▁was ▁ant ic om pet itive ▁with ▁regard ▁to ▁cent rif ug al ▁ev apor ators , ▁requiring ▁Fish er ▁to ▁div est ▁Gene v ac . ▁ ▁In ▁April ▁ 2 0 0 7 , ▁Gene v ac ▁was ▁sold ▁to ▁River la ke ▁Part ners ▁L LC ▁and ▁the ▁mer ger ▁closed ▁with ▁F TC ▁appro val . ▁ ▁Currently , ▁the ▁company ' s ▁products ▁are ▁sold ▁under ▁the ▁brand ▁names ▁of ▁Th ermo ▁Scient ific , ▁Fish er ▁Scient ific , ▁and ▁several ▁other ▁recognized ▁brand ▁names ▁( e . g . ▁Ch rom ac ol , ▁N alg ene , ▁Cell om ics , ▁Pier ce ▁Prote in ▁Research ▁and ▁Fer ment as ). ▁According ▁to ▁company ▁figures , ▁ 4 6 % ▁of ▁its ▁sales ▁are ▁in ▁life ▁sciences , ▁ 2 0 % ▁in ▁health care , ▁and ▁ 3 4 % ▁in ▁industrial / environment al ▁and ▁safety . ▁ ▁Th ermo ▁Fish er ▁has ▁offices ▁and ▁operations ▁in ▁many ▁countries , ▁not ably ▁the ▁U . S . ▁and ▁in ▁Europe . ▁ ▁Ac quisition ▁history ▁ ▁The ▁parent ▁entities , ▁Th ermo ▁Electron ▁and ▁Fish er ▁Scient ific